Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001213900-19-008289
Filing Date
2019-05-10
Accepted
2019-05-10 16:48:44
Documents
5
Effectiveness Date
2019-05-10

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT fs82019_actiniumpharma.htm S-8 82616
2 OPINION OF THE MATT LAW FIRM, PLLC fs82019ex5-1_actinium.htm EX-5.1 5835
3 CONSENT OF MARCUM LLP fs82019ex23-1_actinium.htm EX-23.1 2069
4 CONSENT OF GBH CPAS, PC fs82019ex23-2_actinium.htm EX-23.2 893
5 GRAPHIC exx5-1_img001.jpg GRAPHIC 21381
  Complete submission text file 0001213900-19-008289.txt   122086
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-231391 | Film No.: 19815694
SIC: 2834 Pharmaceutical Preparations